免责申明：华安证券股份有限公司经中国证券监督管理委员会批准，已具备证券投资咨询业务资格。本报告中的信息均来源于合规渠道，华安证券研究所力求准确、可靠，但对这些信息的准确性及完整性均不做任何保证，据此投资，责任自负。 本报告不构成个人投资建议，也没有考虑到个别客户特殊的投资目标、财务状况或需要。客户应考虑本报告中的任何意见或建议是否符合其特定状况。华安证券及其所属关联机构可能会持有报告中提到的公司所发行的证券并进行交易，还可能为这些公司提供投资银行服务或其他服务。 本报告仅向特定客户传送，未经华安证券研究所书面授权，本研究报告的任何部分均不得以任何方式制作任何形式的拷贝、复印件或复制品，或再次分发给任何其他人，或以任何侵犯本公司版权的其他方式使用。如欲引用或转载本文内容，务必联络华安证券研究所并获得许可，并需注明出处为华安证券研究所，且不得对本文进行有悖原意的引用和删改。如未经本公司授权，私自转载或者转发本报告，所引 起的一切后果及法律责任由私自转载或转发者承担。本公司并保留追究其法律责任的权利。 分析师声明：本报告署名分析师具有中国证券业协会授予的证券投资咨询执业资格，以勤勉的执业态度、专业审慎的研究方法，使 ...

从主办方"扫楼"推介被误认为"骗子"，到如今每年吸引数千家企业争相参与；从综合赛道的"大而 全"PK，到近20条细分产业赛道的"精而深"挖掘；从提供奖金扶持，到构建"创投贷保服"科技金融生 态、开放城市应用场景。一条清晰的"培育—成长—上市"科创链条正在广州加速形成。 广州市科技局局长谢明道出了广州双创大赛的创办初心："希望让更多优秀企业站在广州创新舞台的'C 位'，被更多投资者发现。" 然而这并非一日之功。"最开始企业对大赛知晓度连5%都不到。"大湾区科技创新服务中心党支部书 记、董事长秦海鸥回忆，广州双创大赛创办初期，团队通过电话主动对接企业，坚持联合科技园区"扫 楼"走访，曾被不少企业误认为是"骗子"。 10年来，广州科技创新创业大赛（简称"广州双创大赛"）已构建起"平台—场景—资本—服务"四位一体 的服务体系，不单单局限于赛事，更成为凝聚创新资源的平台：累计吸引超3万家企业参赛，推动360家 广州企业斩获国赛奖项，培育出205家国家级专精特新"小巨人"企业、14家上市公司。 发现"种子选手" 归谷科技园。 从"扫楼"走访到千企参赛 随着知名度的攀升，参赛企业从一开始的两三百家到现如今的几千家，广州双创 ...

据介绍，细胞治疗等再生医学技术，是利用干细胞和免疫细胞的特性，激活和修复组织器官，被誉为 是"第三次医学革命"。当前，全球细胞治疗市场规模已突破4000亿美元。湖南省正着力打造千亿级干细 胞与再生医学产业链，长沙市、湘江新区创新联动，指导湖南大学联合共建"再生医学临床研究中心"， 旨在以临床需求为先导，以技术创新为引擎，通过政策创新、平台支撑和产业链协同，加速形成"基础 研究-技术开发-临床应用-产业转化"的闭环。 湖南大学副校长李肯立表示："中心将聚焦关键核心技术突破与解决临床应用相结合，建立完善干细胞 溯源体系的细胞种子库与再生医学产品库，打造具有国际水平的干细胞与再生医学产品应用检测中心， 搭建再生医学临床应用转化平台，力争在再生医学领域人才培养、技术开发、临床试验、推广应用等方 面产出更多高质量创新成果，助推生物医药产业高质量发展。" 中证报中证网讯(记者吴科任)12月21日，湖南大学再生医学临床研究中心在长沙市岳麓科创港授牌启 动。该中心由湖南大学牵头，联合湖南省肿瘤医院、湘雅医院器官损伤衰老与再生医学湖南省重点实验 室、湘潭市中心医院、长沙市第三医院、长沙市口腔医院、长沙市妇幼保健院、湖南达嘉维康 ...

"达嘉维康再生医学研究院是达嘉维康在生命健康领域的重要战略布局，作为中心共建单位，将全程投入技术、人才、资 金，加速推动前沿疗法从实验室走向临床实践"。湖南达嘉维康医药产业股份有限公司（以下简称"达嘉维康"）董事长王毅清 表示，已经为中心工作开展建设了符合GMP标准的细胞库与实验室、国际标准样本存储库，打造从细胞采集、存储、制备到应 用的完整产业链，不断提升产品的安全性、有效性，让老百姓面对细胞治疗产品敢用、想用、用得上。 （编辑 郭之宸） 该中心由湖南大学牵头，联合湖南省肿瘤医院、湘雅医院器官损伤衰老与再生医学湖南省重点实验室、湘潭市中心医院、 长沙市第三医院、长沙市口腔医院、长沙市妇幼保健院、湖南达嘉维康再生医学研究院共同组建，旨在整合"产学研医"协同创 新优势，聚焦重大疾病诊断治疗、组织器官损伤修复等领域，以临床带动科研，以专业赋能产业，开辟一条科研与产业融合发 展的新路径，引领再生医学产业高质量发展。 细胞治疗等再生医学技术，是利用干细胞和免疫细胞的特性，激活和修复组织器官，被誉为是"第三次医学革命"。当前， 全球细胞治疗市场规模已突破4000亿美元。湖南省正着力打造千亿元级干细胞与再生医学产业链，长 ...

嘉宾简介： 脑中风（脑卒中）以其高发病率、高致残率，已成为威胁国民健康的"头号杀手"。尽管急性期的血 管再通技术（如取栓）取得了长足进步，但众多患者仍不可避免地留下严重的神经功能缺损，陷入漫长 的康复困境，为家庭与社会带来沉重负担。在这一背景下，再生医学，尤其是干细胞疗法，为破解神经 修复这一世界性难题带来了全新曙光。 12月5日16:00，首都医科大学附属北京安贞医院神经外科主任医师霍晓川，森普瑞斯（北京）细胞 技术有限公司创始人、董事长李丽做客直播间，围绕干细胞疗法的科学原理、临床证据、安全边界与未 来前景，进行一场兼具专业深度与科普温度的权威解读。、 霍晓川，首都医科大学附属北京安贞医院神经外科主任医师，中国卒中学会神经介入分会青委会委 员，获王忠诚中国神经外科医师年度青年医师奖，首医基础-临床联合实验室"脑心共患病研究"负责 人。《中国卒中杂志》编委、审稿专家。 李丽，森普瑞斯（北京）细胞技术有限公司创始人、董事长。 ...

Group 1: Financing Overview - The technology and manufacturing sectors saw over 30 financing cases and multiple transactions exceeding 100 million RMB, with significant investments in AI, semiconductors, and commercial aerospace [1] - A total of 36 financing events occurred in the domestic primary market from November 17 to November 23, with 31 disclosing amounts totaling approximately 4.55 billion RMB [1] Group 2: Sector-Specific Financing - The advanced manufacturing sector led with 10 financing cases totaling about 1.05 billion RMB, followed by the biomedicine sector with 7 cases at approximately 750 million RMB, and the artificial intelligence sector with 4 cases totaling around 760 million RMB [3] - The medical health sector showed robust activity with significant transactions, including 500 million RMB for Repu Morning and 60 million USD for Tuoji Medicine, focusing on regenerative medicine and innovative medical devices [1][24] Group 3: Regional Financing Distribution - The financing activities were primarily concentrated in Zhejiang, Shanghai, and Jiangsu provinces, with 9, 8, and 7 cases respectively [5] Group 4: Active Investment Institutions - Qiming Venture Partners and Sequoia China were notably active, with Qiming completing 4 financing cases and Sequoia completing 3, mainly in technology and healthcare sectors [8] Group 5: Notable Company Financing - Star Motion Era secured nearly 1 billion RMB in A+ round financing, led by Geely Capital, focusing on humanoid robot development [39] - Repu Morning achieved 500 million RMB in A+ round financing, emphasizing its disruptive regenerative medicine technology [24] - Mingche Bio completed several million RMB in A round financing, specializing in ophthalmic medical devices [13]

Group 1 - The technology and manufacturing sectors have seen over 30 financing cases and multiple transactions exceeding 100 million RMB, with significant investments in AI, semiconductors, and high-end manufacturing [1] - The healthcare sector is also robust, with large transactions such as 500 million RMB for Repu Morning and 6 million USD for Tuoji Medicine, focusing on regenerative medicine and innovative medical devices [1][2] - The overall financing events in the domestic primary market totaled approximately 4.55 billion RMB from November 17 to November 23, with 36 financing events reported [1] Group 2 - The advanced manufacturing sector led with 10 financing cases totaling about 1.05 billion RMB, followed by the biomedicine sector with 7 cases at approximately 750 million RMB, and the AI sector with 4 cases at around 760 million RMB [2] - The financing activities were concentrated in regions such as Zhejiang, Shanghai, and Jiangsu, with 9, 8, and 7 financing cases respectively [3] - Active investment institutions included Qiming Venture Partners and Sequoia China, with Qiming completing 4 financing cases and Sequoia completing 3, primarily in technology, manufacturing, and healthcare sectors [4] Group 3 - Companies like Bilin Information and Xianbing Sister have completed significant financing rounds, with Bilin receiving several million RMB for its tourism media platform and Xianbing Sister securing 20 million RMB for its heritage food brand [5][6] - Mingche Bio, focusing on ophthalmic medical devices, completed several million RMB in financing, while Anxin Medical, specializing in women's health, also secured significant angel funding [7][8] - Other notable financing events include Deli Furu's A round, Newborn's over 100 million RMB A round, and Star Motion Era's nearly 1 billion RMB A+ round, indicating strong investor interest in innovative technology and healthcare solutions [10][18][36]

项目负责人伊万·马丁教授表示："尽管小鼠模型为骨髓研究奠定了基础，但人类与动物的生物学差异显 著。新模型能更精准地模拟人体造血机制，尤其在疾病建模和药物筛选中具有不可替代的优势。" 团队成员安德烈斯·加西亚博士补充道，该系统有望减少血癌研究中对动物试验的依赖，符合科研伦理 中"替代、减少、完善"的原则。不过，当前模型尺寸较大，若用于高通量药物测试，需进一步微型化以 适应多化合物并行实验的需求。 这项研究不仅为血液疾病机制探索提供了新工具，更标志着人类在体外模拟复杂器官功能领域迈出了关 键一步。未来，该技术或可拓展至个性化医疗领域。通过提取患者自身细胞构建专属骨髓模型，医生能 提前测试不同疗法的效果，为血癌患者定制最优治疗方案。团队强调，这一应用目前仍需克服技术瓶 颈，距离临床落地尚需时日。（记者张梦然） 瑞士巴塞尔大学研究团队在最新一期《细胞·干细胞》上发表了一项突破性成果：他们首次在实验室中 用人类细胞构建出高度仿真的三维骨髓组织模型。该模型完整复现了骨髓中血管、骨细胞、神经及免疫 细胞等复杂结构，为血癌研究、药物测试及替代动物试验提供了全新平台。 骨髓作为人体"血液工厂"，其内部由多种细胞构成的微环境对血 ...

Core Insights - A research team from the University of Basel has developed a highly realistic three-dimensional bone marrow tissue model using human cells, marking a significant advancement in the field of blood cancer research and drug testing [2][3] - The new model replicates the complex structures of bone marrow, including blood vessels, bone cells, nerves, and immune cells, providing a new platform for research that overcomes the limitations of traditional animal models and simplified two-dimensional cell cultures [2][4] Summary by Sections - **Research Breakthrough**: The model is constructed using hydroxyapatite as a scaffold combined with induced pluripotent stem cells, allowing for the cultivation of a three-dimensional bone marrow tissue that closely resembles human tissue in both cellular composition and spatial structure [2] - **Implications for Blood Cancer Research**: The model can maintain human blood generation activity for several weeks, offering a more accurate simulation of human hematopoiesis, which is crucial for disease modeling and drug screening [2][3] - **Ethical Considerations**: This system is expected to reduce reliance on animal testing in blood cancer research, aligning with the principles of "replacement, reduction, refinement" in scientific research ethics [2] - **Future Applications**: The technology may extend to personalized medicine, allowing for the creation of patient-specific bone marrow models to test various therapies, although technical challenges remain before clinical application can be realized [3][4] - **Potential Impact on Biomedical Research**: This advancement represents a milestone in regenerative medicine and translational research, potentially addressing ethical dilemmas and time constraints in drug development [4]

Core Insights - A research team from the University of Basel has developed a highly realistic 3D bone marrow tissue model using human cells, which replicates the complex structures found in bone marrow, providing a new platform for blood cancer research, drug testing, and reducing reliance on animal testing [1][2]. Group 1: Research and Development - The new model utilizes hydroxyapatite as a scaffold combined with induced pluripotent stem cells, allowing for the cultivation of a 3D bone marrow tissue that maintains human blood generation activity for several weeks [1]. - The model's dimensions are 8 millimeters in diameter and 4 millimeters in thickness, closely resembling the cellular composition and spatial structure of real human tissue [1]. Group 2: Implications for Medicine - This research marks a significant advancement in the field of regenerative medicine and translational research, potentially transforming disease research, high-throughput drug screening, and personalized treatment [2][3]. - The technology may enable the creation of personalized bone marrow models from patients' own cells, allowing doctors to test various therapies in advance to tailor optimal treatment plans for blood cancer patients [2]. Group 3: Ethical Considerations - The new model aligns with the ethical principles of "replacement, reduction, and refinement" in research, aiming to decrease the dependence on animal testing in blood cancer studies [1][3].